KR20200027976A - 파킨슨병의 예방 및/또는 지지 요법적 치료에 사용을 위한 프로피온산 및/또는 부티르산 - Google Patents

파킨슨병의 예방 및/또는 지지 요법적 치료에 사용을 위한 프로피온산 및/또는 부티르산 Download PDF

Info

Publication number
KR20200027976A
KR20200027976A KR1020207003431A KR20207003431A KR20200027976A KR 20200027976 A KR20200027976 A KR 20200027976A KR 1020207003431 A KR1020207003431 A KR 1020207003431A KR 20207003431 A KR20207003431 A KR 20207003431A KR 20200027976 A KR20200027976 A KR 20200027976A
Authority
KR
South Korea
Prior art keywords
propionic acid
butyric acid
disease
parkinson
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207003431A
Other languages
English (en)
Korean (ko)
Inventor
호르스트 프르춘테크
아이덴 하기키아
Original Assignee
호르스트 프르춘테크
아이덴 하기키아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 호르스트 프르춘테크, 아이덴 하기키아 filed Critical 호르스트 프르춘테크
Publication of KR20200027976A publication Critical patent/KR20200027976A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/05—Propionic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020207003431A 2017-07-13 2018-07-13 파킨슨병의 예방 및/또는 지지 요법적 치료에 사용을 위한 프로피온산 및/또는 부티르산 Ceased KR20200027976A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017115819.7 2017-07-13
DE102017115819.7A DE102017115819A1 (de) 2017-07-13 2017-07-13 Mittel zur prophylaktischen und/oder unterstützenden therapeutischen Behandlung von Morbus Parkinson
PCT/EP2018/069089 WO2019012108A1 (de) 2017-07-13 2018-07-13 Propion- und/oder buttersäure zur verwendung zur prophylaktischen und/oder unterstützenden therapeutischen behandlung von morbus parkinson

Publications (1)

Publication Number Publication Date
KR20200027976A true KR20200027976A (ko) 2020-03-13

Family

ID=63108510

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003431A Ceased KR20200027976A (ko) 2017-07-13 2018-07-13 파킨슨병의 예방 및/또는 지지 요법적 치료에 사용을 위한 프로피온산 및/또는 부티르산

Country Status (10)

Country Link
US (2) US20200163914A1 (enExample)
EP (1) EP3651754B1 (enExample)
JP (1) JP7206223B2 (enExample)
KR (1) KR20200027976A (enExample)
CN (1) CN110996933A (enExample)
AU (2) AU2018298862A1 (enExample)
BR (1) BR112020000570A2 (enExample)
CA (1) CA3067728A1 (enExample)
DE (1) DE102017115819A1 (enExample)
WO (1) WO2019012108A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021048440A1 (en) 2019-09-13 2021-03-18 Basf Se Composition for the treatment of neurodegenerative diseases
CN111450238A (zh) * 2020-03-31 2020-07-28 上海交通大学医学院附属瑞金医院 骨钙素或丙酸在制备抗帕金森病药物中的应用
CN113332266A (zh) * 2021-06-10 2021-09-03 徐州医科大学 含丁酸的治疗与预防神经退行性疾病的药物及丁酸的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19503598A1 (de) * 1995-02-03 1996-08-08 Zuzana Dr Cully Verfahren zur fermentativen Herstellung von Propionsäure oder Buttersäure bzw. deren Salze
NL1009990C2 (nl) * 1998-09-02 2000-03-15 Sibeco Chemicals Voedingssupplement en werkwijze voor het vervaardigen van zulk voedingssupplement.
US20060105962A1 (en) * 2004-11-14 2006-05-18 Robinson Robert O A Tonic to maintain intestinal flora
WO2012095461A1 (de) * 2011-01-12 2012-07-19 Albert Daxer Getränk
EP3019181A4 (en) * 2013-07-09 2016-09-21 Puretech Ventures Llc COMPOSITIONS WITH COMBINATIONS OF BIOACTIVE MOLECULARS DERIVED FROM MICROBOTS FOR TREATING DISEASES
CN105055457A (zh) * 2015-08-06 2015-11-18 温州医科大学附属第二医院 一种防治阿尔茨海默病的药物及其制备方法和应用
DE102016103242A1 (de) * 2016-02-24 2017-08-24 Flexopharm Brain Gmbh & Co. Kg Mittel zur unterstützenden Immunmodulation
WO2017091072A1 (en) * 2015-11-27 2017-06-01 Birrbeheer B.V. Butyrate salts for use in inflammatory diseases
US11065217B2 (en) * 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders

Also Published As

Publication number Publication date
US20200163914A1 (en) 2020-05-28
EP3651754A1 (de) 2020-05-20
DE102017115819A1 (de) 2019-01-17
AU2021273627A1 (en) 2021-12-16
CA3067728A1 (en) 2019-01-17
BR112020000570A2 (pt) 2020-07-14
JP2020526485A (ja) 2020-08-31
CN110996933A (zh) 2020-04-10
WO2019012108A1 (de) 2019-01-17
US20220313634A1 (en) 2022-10-06
EP3651754C0 (de) 2025-04-30
AU2021273627B2 (en) 2024-01-25
EP3651754B1 (de) 2025-04-30
JP7206223B2 (ja) 2023-01-17
AU2018298862A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
TWI580427B (zh) Compositions for reducing body weight and reducing body fat, and pharmaceuticals and applications thereof
CN102665725B (zh) 高血脂症改善剂、贫血改善组合物、尿酸值降低组合物以及饮料食品
US11471432B2 (en) Supporting immunomodulatory agent
US20220313634A1 (en) Agent for the prophylactic and/or supportive therapeutic treatment of parkinson's disease
IL200929A (en) Magnesium compositions and uses thereof
WO2007119578A1 (ja) 神経系細胞機能改善剤
TWI337066B (en) Dietary supplement
JP2007238441A (ja) アスタキサンチンを有効成分とする体脂肪減少用組成物
KR20220154210A (ko) 코엔자임 q(coenzyme q) 생산 촉진제 및 코엔자임 q 생산 촉진 방법
US10682322B2 (en) Supporting immunomodulatory agent
JP6218870B2 (ja) ジンセノサイドｆ２を含む非アルコール性肝疾患又はインスリン抵抗性の予防若しくは治療用組成物
WO2013122235A1 (ja) メタボリックシンドロームの予防、改善または治療用組成物
JPH09255570A (ja) 血中脂質濃度を低減させる薬剤及び可食性組成物
NO20001717L (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
US20130022673A1 (en) Enhancement of magnesium uptake in mammals
JP2009107987A (ja) 筋力向上剤
RU2670612C2 (ru) Композиция для предупреждения или лечения ожирения, содержащая α-липоевую кислоту и N-ацетилцистеин в качестве активных ингредиентов
US11458150B2 (en) Methylphosphinic acid compositions and methods for reducing aging
JP2000281583A (ja) 桑の葉を含有する健康補助製剤及び健康補助飲食品
JP2010090097A (ja) 抗骨粗鬆症組成物
JP2010265186A (ja) 貧血予防用組成物
JP2004292355A (ja) 抗ストレス剤
JP2006213667A (ja) アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
JP2025513918A (ja) 新規なビフィドバクテリウムビフィダムｈｅｍ９７２菌株、及び前記菌株又はその培養物を含む腸内環境改善用組成物
AU2024253060A1 (en) Oral active ingredient combination containing l-arginine, l-citrulline, selenite and water-soluble boron

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210701

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231217

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241029

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D